Current Liabilities decreased faster than Rezolute Inc 's Cash & cash equivalent, this led to improvement in Rezolute Inc 's Quick Ratio to 9.51, Quick Ratio remained below Rezolute Inc average.

Within Major Pharmaceutical Preparations industry 113 other companies have achieved higher Quick Ratio than Rezolute Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 209 to 487.

Explain Quick Ratio?
How much Cash & cash equivalents RZLT�s has?
What are RZLT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RZLT/financial-strength

https://api.csimarket.com/api/v1/companies/RZLT/fundamentals

https://api.csimarket.com/api/v1/companies/RZLT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RZLT Quick Ratio	(Sep 30 2026) Q1	(Jun 30 2026) Q4	(Mar 31 2026) Q3	(Dec 31 2025) Q2	(Sep 30 2025) Q1
Y / Y Current Liabilities Change	-7.31 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-40.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	9.51	Subscribe	Subscribe	Subscribe	Subscribe
RZLT's Total Ranking	# 487	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-17.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-16.51 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 114
Healthcare Sector	# 172
Overall Market	# 487

Quick Ratio Statistics
High	Average	Low
63.53	9.55	0
(Sep 30 2022)		(Dec 31 2013)

Financial Statements
Rezolute Inc 's Current Liabilities	$ 9 Millions	Visit RZLT's Balance sheet
Rezolute Inc 's Cash & cash equivalent	$ 90 Millions	Visit RZLT's Balance sheet
Source of RZLT's Sales		Visit RZLT's Sales by Geography

Cumulative Rezolute Inc 's Quick Ratio

RZLT's Quick Ratio for the trailling 12 Months

RZLT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-21.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-11.96 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	13.3	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3721	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-2.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-12.12 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RZLT Financial Strength Comparisons >> Go to Compare RZLT Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in RZLT's Current Liabilities to $9.46 millions, cumulative Quick Ratio to 13.3 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Rezolute Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2026 from 2533 to 3721.

Explain Quick Ratio?
How much Cash & cash equivalents RZLT�s has?
What are RZLT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 428
Healthcare Sector	# 872
Within the Market	# 3721

trailing twelve months Quick Ratio Statistics
High	Average	Low
36.56	6.96	0.11
(Dec 31 2022)		(Dec 31 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Silo Pharma Inc	22.91	$ 8.051 Millions	$ 0.351 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Silence Therapeutics Plc	22.00	$ 247.659 Millions	$ 11.259 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Nektar Therapeutics	20.21	$ 1,525.156 Millions	$ 75.478 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Benitec Biopharma Inc	18.38	$ 176.368 Millions	$ 9.594 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Monopar Therapeutics Inc	17.65	$ 52.634 Millions	$ 2.982 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Jade Biosciences Inc	15.70	$ 475.706 Millions	$ 30.293 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions

Date modified: 2026-11-08T19:43:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.